Patient Pain and Function in Medial Knee Osteoarthritis After Anteromedial vs Anterolateral Intra-Articular Corticosteroid Injection (Medial OA CSI)

August 31, 2026 updated by: University of Chicago

Does Injection Site (Anteromedial vs Anterolateral) Affect Pain Relief After Intra-Articular Corticosteroid Injection in Moderate-to-Severe Medial Knee Osteoarthritis?

The primary purpose of this study is to find out if there is a difference in pain experienced in patients with knee arthritis of the inside of their knee if they get a steroid injection on the inside or outside of their knee. Participants will:

  1. Be randomly divided into getting their steroid injection on the inside or outside of their knee.
  2. Answer a pain survey before their injection as well as over the phone 2 weeks, 6 weeks, and 12 weeks after their injection.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Illinois
      • Bolingbrook, Illinois, United States, 60440
        • Recruiting
        • Bolingbrook Clinic
        • Contact:
        • Principal Investigator:
          • Brandon Pardi, M.D.
      • Chicago, Illinois, United States, 60637
        • Recruiting
        • Hyde Park Clinic
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sara JS Wallace, M.D./M.P.H.
      • La Grange, Illinois, United States, 60525
        • Recruiting
        • La Grange Clinic
        • Principal Investigator:
          • Sara JS Wallace, M.D./M.P.H.
        • Contact:
      • Orland Park, Illinois, United States, 60462
        • Recruiting
        • Orland Park Clinic
        • Principal Investigator:
          • Sara JS Wallace, M.D./M.P.H.
        • Contact:
        • Contact:
      • Woodridge, Illinois, United States, 60517
        • Recruiting
        • Woodridge Clinic
        • Contact:
        • Principal Investigator:
          • Brandon Pardi, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 40
  • Clinical diagnosis of knee OA with predominant medial compartment symptoms
  • Radiographic moderate-to-severe medial compartment OA (KL grade 3-4 or equivalent)
  • Agreed to and preparing to receive a CSI of the knee as part of standard care from surgeon, regardless of past injection of the knee
  • Able to provide informed consent
  • Able to complete phone, email, or MyChart follow-ups in English

Exclusion Criteria:

  • Predominant lateral compartment OA or patellofemoral-only OA
  • Inflammatory arthritis (RA, gout flare, etc.)
  • Suspected or confirmed joint infection or overlying cellulitis
  • Prior knee arthroplasty on the index knee
  • Planned surgery for index knee within 12-week follow-up
  • Inability to complete follow-up assessments
  • Other clinician-determined contraindication to CSI

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Anterolateral
These patients will receive their corticosteroid injections on their anterolateral knees.
Procedure: Anterolateral Injection
If randomized to this intervention, patients will receive a corticosteroid injection on the anterolateral side of their knee.
Active Comparator: Anteromedial
This group of patients will receive injections on the anteromedial side of their knee.
Procedure: Anteromedial Injection
If randomized to this intervention, patients will receive a corticosteroid injection in the anteromedial side of their knee.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numeric Pain Rating Scale
Time Frame: Pre-procedure, 2 weeks, 6 weeks, and 12 weeks post-injection
This survey asks patients to rate their pain on a scale from 0 to 10.
Pre-procedure, 2 weeks, 6 weeks, and 12 weeks post-injection
Knee Osteoarthritis and Outcome Score-Joint Replacement
Time Frame: Pre-procedure, 2 weeks, 6 weeks, and 12 weeks post-injection
This standardized survey asks patients to describe the impact of their knee stiffness and pain on daily tasks.
Pre-procedure, 2 weeks, 6 weeks, and 12 weeks post-injection

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Institutional Survey on Satisfaction with Injection
Time Frame: 2 weeks, 6 weeks, and 12 weeks post-injection
This survey asks patients to rate their satisfaction with their corticosteroid injection on a scale from 0 to 10.
2 weeks, 6 weeks, and 12 weeks post-injection
Patient Global Impression of Change
Time Frame: 2 weeks, 6 weeks, and 12 weeks post-injection
This survey asks patients to rate their overall health status on a scale from 1 to 7.
2 weeks, 6 weeks, and 12 weeks post-injection

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Chicago

Collaborators

AdventHealth

Investigators

  • Principal Investigator: Sara JS Wallace, M.D./M.P.H., The University of Chicago Medical Center
  • Principal Investigator: Brandon Pardi, M.D., AdventHealth

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 31, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

August 31, 2026

First Submitted That Met QC Criteria

August 31, 2026

First Posted (Actual)

September 4, 2026

Study Record Updates

Last Update Posted (Actual)

September 4, 2026

Last Update Submitted That Met QC Criteria

August 31, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB26-0169

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

IPD may not be shared due to privacy concerns, but the authors will consider sharing de-identified data upon reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe